Cite
HARVARD Citation
Attauabi, M. et al. (n.d.). P347 Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases. Journal of Crohn's and colitis. pp. S369-S370. [Online].